» Articles » PMID: 34394004

The Potential Causes of Cystic Fibrosis-Related Diabetes

Overview
Specialty Endocrinology
Date 2021 Aug 16
PMID 34394004
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (). Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity, affecting more than 50% of adult CF patients. Despite this high prevalence, the etiology of CFRD remains incompletely understood. Studies in young CF children show pancreatic islet disorganization, abnormal glucose tolerance, and delayed first-phase insulin secretion suggesting that islet dysfunction is an early feature of CF. Since insulin-producing pancreatic β-cells express very low levels of CFTR, CFRD likely results from β-cell extrinsic factors. In the vicinity of β-cells, CFTR is expressed in both the exocrine pancreas and the immune system. In the exocrine pancreas, CFTR mutations lead to the obstruction of the pancreatic ductal canal, inflammation, and immune cell infiltration, ultimately causing the destruction of the exocrine pancreas and remodeling of islets. Both inflammation and ductal cells have a direct effect on insulin secretion and could participate in CFRD development. CFTR mutations are also associated with inflammatory responses and excessive cytokine production by various immune cells, which infiltrate the pancreas and exert a negative impact on insulin secretion, causing dysregulation of glucose homeostasis in CF adults. In addition, the function of macrophages in shaping pancreatic islet development may be impaired by CFTR mutations, further contributing to the pancreatic islet structural defects as well as impaired first-phase insulin secretion observed in very young children. This review discusses the different factors that may contribute to CFRD.

Citing Articles

Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review.

Ahmed A, Ankireddypalli A, Harindhanavudhi T, Moran A, Moheet A J Clin Transl Endocrinol. 2025; 38:100375.

PMID: 39764279 PMC: 11702000. DOI: 10.1016/j.jcte.2024.100375.


Cystic fibrosis-related metabolic defects: crosstalk between ion channels and organs.

Sims-Lucas S, Goetzman E, Kleyman T J Clin Invest. 2024; 134(13).

PMID: 38949023 PMC: 11213462. DOI: 10.1172/JCI182329.


Association between cystic fibrosis transmembrane regulator genotype and clinical outcomes, glucose homeostasis indices and CF-related diabetes risk in adults with CF.

Belanger N, Bonhoure A, Kherani T, Boudreau V, Tremblay F, Lavoie A Genet Mol Biol. 2024; 47(1):e20230021.

PMID: 38558018 PMC: 10993309. DOI: 10.1590/1678-4685-GMB-2023-0021.


The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis.

Kirigin Bilos L, Altabas V, Vukic Dugac A, Baretic M Medicina (Kaunas). 2024; 60(3).

PMID: 38541202 PMC: 10972086. DOI: 10.3390/medicina60030477.


What the future holds: cystic fibrosis and aging.

Blankenship S, Landis A, Harrison Williams E, Lever J, Garcia B, Solomon G Front Med (Lausanne). 2024; 10:1340388.

PMID: 38264036 PMC: 10804849. DOI: 10.3389/fmed.2023.1340388.


References
1.
Polverino F, Lu B, Quintero J, Vargas S, Patel A, Owen C . CFTR regulates B cell activation and lymphoid follicle development. Respir Res. 2019; 20(1):133. PMC: 6604167. DOI: 10.1186/s12931-019-1103-1. View

2.
Meacham L, CAPLAN D, McKean L, Buchanan C, Parks J, Culler F . Preservation of somatostatin secretion in cystic fibrosis patients with diabetes. Arch Dis Child. 1993; 68(1):123-5. PMC: 1029198. DOI: 10.1136/adc.68.1.123. View

3.
Lara-Reyna S, Scambler T, Holbrook J, Wong C, Jarosz-Griffiths H, Martinon F . Metabolic Reprograming of Cystic Fibrosis Macrophages via the IRE1α Arm of the Unfolded Protein Response Results in Exacerbated Inflammation. Front Immunol. 2019; 10:1789. PMC: 6687873. DOI: 10.3389/fimmu.2019.01789. View

4.
Minicucci L, Lorini R, Giannattasio A, Colombo C, Iapichino L, Reali M . Liver disease as risk factor for cystic fibrosis-related diabetes development. Acta Paediatr. 2007; 96(5):736-9. DOI: 10.1111/j.1651-2227.2007.00250.x. View

5.
Maloy A, Longnecker D, Greenberg E . The relation of islet amyloid to the clinical type of diabetes. Hum Pathol. 1981; 12(10):917-22. DOI: 10.1016/s0046-8177(81)80197-9. View